Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer.

Abstract

BACKGROUND:

Cancer-testis antigens (CTAs) are tumor antigens that are normally expressed in the testes but are aberrantly expressed in several cancers. CTA overexpression drives the metastasis and progression of lung cancer, and is associated with poor prognosis. To improve lung cancer diagnosis, prognostic prediction, and drug discovery, robust CTA identification and quantitation is needed. In this study, we examined and quantified the co-expression of CTAs in lung cancer to derive cancer testis antigen burden (CTAB), a novel biomarker of immunotherapy response.

METHODS:

Formalin fixed paraffin embedded (FFPE) tumor samples in discovery cohort (n = 5250) and immunotherapy and combination therapy treated non-small cell lung cancer (NSCLC) retrospective (n = 250) cohorts were tested by comprehensive genomic and immune profiling (CGIP), including tumor mutational burden (TMB) and the mRNA expression of 17 CTAs. PD-L1 expression was evaluated by IHC. CTA expression was summed to derive the CTAB score. The median CTAB score for the discovery cohort of 170 was applied to the retrospective cohort as cutoff for CTAB "high" and "low". Biomarker and gene expression correlation was measured by Spearman correlation. Kaplan-Meier survival analyses were used to detect overall survival (OS) differences, and objective response rate (ORR) based on RECIST criteria was compared using Fisher's exact test.

RESULTS:

The CTAs were highly co-expressed (p < 0.05) in the discovery cohort. There was no correlation between CTAB and PD-L1 expression (R = 0.011, p = 0.45) but some correlation with TMB (R = 0.11, p = 9.2 × 10-14). Kaplan-Meier survival analysis of the immunotherapy-treated NSCLC cohort revealed better OS for the pembrolizumab monotherapy treated patients with high CTAB (p = 0.027). The combination group demonstrated improved OS compared to pembrolizumab monotherapy group (p = 0.04). The pembrolizumab monotherapy patients with high CTAB had a greater ORR than the combination therapy group (p = 0.02).

CONCLUSIONS:

CTA co-expression can be reliably measured using CGIP in solid tumors. As a biomarker, CTAB appears to be independent from PD-L1 expression, suggesting that CTAB represents aspects of tumor immunogenicity not measured by current standard of care testing. Improved OS and ORR for high CTAB NSCLC patients treated with pembrolizumab monotherapy suggests a unique underlying aspect of immune response to these tumor antigens that needs further investigation.

• Authors: R J Seager, Maria-Fernanda Senosain, Erik Van Roey, Shuang Gao, Paul DePietro, Mary K Nesline, Durga Prasad Dash, Shengle Zhang, Heidi Ko, Stephanie B Hastings, Kyle C Strickland, Rebecca A Previs, Taylor J Jensen, Marcia Eisenberg, Brian J Caveney, Eric A Severson, Shakti Ramkissoon, Jeffrey M Conroy, Sarabjot Pabla
• Journal: Journal of translational medicine (J Transl Med) Vol. 22 Issue 1 Pg. 141 (Feb 07 2024) ISSN: 1479-5876 [Electronic] England
• PMID: 38326843 (Publication Type: Journal Article)
• Copyright: © 2024. The Author(s).

Chemical References

• B7-H1 Antigen
• Cetrimonium
• Antigens, Neoplasm
• Biomarkers, Tumor

Topics

• Humans
• Male
• Lung Neoplasms (drug therapy)
• Carcinoma, Non-Small-Cell Lung (pathology)
• B7-H1 Antigen (metabolism)
• Cetrimonium (therapeutic use)
• Retrospective Studies
• Testis (chemistry, metabolism, pathology)
• Antigens, Neoplasm
• Biomarkers, Tumor (genetics)